Last reviewed 2026-05-14 · How we verify

Dexmedetomidine 0.5μg／kg

Dexmedetomidine 0.5μg／kg is a Alpha-2 adrenergic receptor agonist Small molecule drug developed by Eye & ENT Hospital of Fudan University. It is currently FDA-approved for Sedation in perioperative and intensive care unit settings, Analgesia and anxiolysis in procedural sedation. Also known as: Dexmedetomidine Hydrochloride Injection.

Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.

Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system. Used for Sedation in perioperative and intensive care unit settings, Analgesia and anxiolysis in procedural sedation.

At a glance

Mechanism of action

Dexmedetomidine binds with high selectivity to alpha-2 adrenergic receptors, particularly in the locus coeruleus and other brainstem regions, leading to decreased norepinephrine release and reduced neuronal firing. This results in a unique sedative state characterized by maintained airway reflexes and the ability to be aroused, along with analgesic and anxiolytic effects. The drug is commonly used for sedation in perioperative and intensive care settings.

Approved indications

• Sedation in perioperative and intensive care unit settings
• Analgesia and anxiolysis in procedural sedation

Common side effects

• Hypotension
• Bradycardia
• Dry mouth
• Hypertension (transient, initial)
• Dizziness

Key clinical trials

• Effect of OFA, OSA Versus Opioid-based Anesthesia on NETs and Cancer Cell Malignancy After Colorectal Cancer Surgery (NA)
• Efficacy Study of Dexmedetomidine Nasal Spray Combined With Propofol for Deep Sedation in ERCP (NA)
• The Improvement of Low-dose Esketamine on Postoperative Depression in Patients Undergoing Bariatric Surgery With Preoperative Depression (PHASE4)
• DexmedetOmidine Complement Treats Chronic insOmnia and Improves Circadian Rhythm (DOCTOR) (NA)
• Comparative Efficacy & Safety of Dexmedetomidine vs Tramadol in Paeds Hernioraphy. A Caudal Anaesthesia Approach (PHASE2, PHASE3)
• Analgesic Efficacy of Ropivacaine Alone or in Combination With Adjuvants on Post-operative Analgesia Following Video-Assisted Thoracoscopic Surgery. (PHASE4)
• Advanced Analgesia on the Quality of Recovery After General Anesthesia in Elderly Patients (PHASE4)
• Analgesia-first Minimal Sedation for Spontaneous Intracerebral Hemorrhage Early Antihypertensive Treatment (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Dexmedetomidine 0.5μg／kg CI brief — competitive landscape report
• Dexmedetomidine 0.5μg／kg updates RSS · CI watch RSS
• Eye & ENT Hospital of Fudan University portfolio CI

Frequently asked questions about Dexmedetomidine 0.5μg／kg

Related

• Drug class: All Alpha-2 adrenergic receptor agonist drugs
• Target: All drugs targeting Alpha-2 adrenergic receptor
• Manufacturer: Eye & ENT Hospital of Fudan University — full pipeline
• Therapeutic area: All drugs in Anesthesia and Sedation
• Indication: Drugs for Sedation in perioperative and intensive care unit settings
• Indication: Drugs for Analgesia and anxiolysis in procedural sedation
• Also known as: Dexmedetomidine Hydrochloride Injection
• Compare: Dexmedetomidine 0.5μg／kg vs similar drugs
• Pricing: Dexmedetomidine 0.5μg／kg cost, discount & access